SK Plasma, a South Korea-based biologic medicine company that develops and manufactures high-quality plasma-derived medicines, plans to invest $250m to build a new blood products manufacturing facility in Jakarta, the capital city of Indonesia.

The plasma fractionation facility will produce products such as immune globulin and albumin, used for patients with immunodeficiency diseases and haemophilia. The plant will be capable of producing one million litres of blood products per year.

SK Plasma is a subsidiary of SK Discovery, which announced in December 2022 that it would be opening a bio strategy and investment division to be led by Kim Jung-hoon, the director of SK Chemicals’ research and development centre.